We focus on discovery of molecular biomarkers of COVID-19 with respect to internal and external exposure factors called exposomes, that can provide early warning for COVID-19 susceptibility and severity, as well as targets for therapeutic modalities. Our approach:
UC San Diego has built a robotic high throughput mass-spec for exposome determination. Amrita will do sequential and concurrent investigation of patient samples and vitals (through wearables and remote monitoring), with overall objective of identifying suspected Early Warning Severity Biomarkers (EWSB) in the exposome. Stanford will develop machine learning algorithms for confirming or controverting EWSB suspects and track clinical trajectory of each patient.
Dr. Shantikumar Nair
Dean of Research, Director
Amrita Center for Nanosciences
Dr. Ekanath Rangan
Physician Scientist
Amrita Institute of Medical Sciences & Research [AIMS]
Dr. Mohit Jain
University of California, San Diego (UCSD)
Dr. Ramesh Rao
University of California, San Diego(UCSD)
Dr. Shriram Nallamshetty
Stanford University